Year: 2016
Type: article
Study design: Observational Study
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a dismal prognostic.KRAS is a well-recognized driver gene in PDAC, detected in the earliest stages of pancreatic tumor transformation.To establish the frequency of KRAS mutations in a cohort of Romanian patients, we performed Sanger sequencing for exon 2 and exon 3 of the gene on 31 PDACs pairs.We further examined correlation of the mutational status with clinico-pathologic data of the patients and evaluated the prognostic implication of KRAS mutations.Ten out of 31 patients (32%) had KRAS missense mutations, all were detected in exon 2, and codon 12 only.Among patients with KRAS mutations, the majority (7/10, 70%) had c.35G>A (p.G12D) substitutions.Patients with p.G12D mutations had a marginally worse survival (p=0.07) and a shorter disease-free survival (p=0.04) when compared to KRAS wild-type patients.Correlation between patients age and recurrence was seen in KRAS wild-type cohort (p=0.096,r=-0.6).In summary, evaluation of KRAS mutational status is a predictor for PDAC patients` prognosis and further KRAS directed therapy might prove to be an efficient tool in patients having KRAS mutations.
Institutions: National Cancer Centre Singapore, Institutul Clinic Fundeni, Agency for Science, Technology and Research, National University of Singapore, Duke-NUS Medical School, Cancer Science Institute of Singapore, Institute of Molecular and Cell Biology, Titu Maiorescu University, Harvard University, Massachusetts General Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2474848182